Oramed Pharmaceuticals (ORMP) Total Non-Current Liabilities (2011 - 2026)

Oramed Pharmaceuticals has reported Total Non-Current Liabilities for 16 years, with the latest figure at $20.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 829.31% year-over-year to $20.0 million; the trailing twelve-month figure through Mar 2026 stood at $20.0 million (up 829.31% YoY), and the FY2025 full-year result was $12.0 million, up 183.42% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $20.0 million, up from $12.0 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $20.0 million in Q1 2026, with the low at $2.2 million in Q1 2025.
• Historically, Total Non-Current Liabilities has averaged $6.0 million across 5 years, with a median of $4.4 million in 2023.
• Annual changes were most pronounced in 2025 — Total Non-Current Liabilities tumbled 50.79% — and 2026, when it jumped 829.31%.
• Oramed Pharmaceuticals' Total Non-Current Liabilities stood at $4.7 million in 2022, then decreased by 6.24% to $4.4 million in 2023, then declined by 4.46% to $4.2 million in 2024, then soared by 183.42% to $12.0 million in 2025, then jumped by 66.26% to $20.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $20.0 million (Q1 2026), $12.0 million (Q4 2025), and $12.0 million (Q3 2025), per Business Quant data.